Basilea Pharmaceutica AG (BPMUF)
USD 47.5
(0.0%)
USD 47.5
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 33.78 Million CHF | 6.43% |
| 2022 | 102.34 Million CHF | -15.44% |
| 2021 | 121.04 Million CHF | -3.16% |
| 2020 | 124.98 Million CHF | -4.72% |
| 2019 | 131.17 Million CHF | -3.79% |
| 2018 | 136.35 Million CHF | 27.87% |
| 2017 | 106.63 Million CHF | 2.01% |
| 2016 | 104.52 Million CHF | -6.49% |
| 2015 | 111.78 Million CHF | 272.54% |
| 2014 | 30 Million CHF | 43.66% |
| 2013 | 20.88 Million CHF | -55.24% |
| 2012 | 46.66 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.66 Million CHF | -89.6% |
| 2024 Q2 | 7.66 Million CHF | 0.0% |
| 2023 Q1 | 8.13 Million CHF | -84.31% |
| 2023 Q4 | 73.62 Million CHF | 779.25% |
| 2023 Q3 | 8.37 Million CHF | -77.97% |
| 2023 Q2 | 38.01 Million CHF | 367.31% |
| 2023 FY | 108.93 Million CHF | 6.43% |
| 2022 Q1 | 7.02 Million CHF | -89.49% |
| 2022 Q4 | 51.85 Million CHF | 657.93% |
| 2022 Q3 | 6.84 Million CHF | -87.04% |
| 2022 Q2 | 52.76 Million CHF | 651.05% |
| 2022 FY | 102.34 Million CHF | -15.44% |
| 2021 Q2 | 56.02 Million CHF | 657.85% |
| 2021 Q4 | 66.84 Million CHF | 802.4% |
| 2021 FY | 121.04 Million CHF | -3.16% |
| 2021 Q1 | 7.39 Million CHF | -89.2% |
| 2021 Q3 | 7.4 Million CHF | -86.78% |
| 2020 FY | 124.98 Million CHF | -4.72% |
| 2020 Q1 | 402 Thousand CHF | -99.39% |
| 2020 Q4 | 68.44 Million CHF | 867.34% |
| 2020 Q2 | 58.38 Million CHF | 14424.38% |
| 2020 Q3 | 7.07 Million CHF | -87.88% |
| 2019 FY | 131.17 Million CHF | -3.79% |
| 2019 Q4 | 65.7 Million CHF | 861.78% |
| 2019 Q1 | 7.58 Million CHF | -11.52% |
| 2019 Q3 | 6.83 Million CHF | -89.81% |
| 2019 Q2 | 67 Million CHF | 783.21% |
| 2018 FY | 136.35 Million CHF | 27.87% |
| 2018 Q3 | 8.57 Million CHF | 15.91% |
| 2018 Q2 | 7.39 Million CHF | 0.0% |
| 2018 Q1 | 7.39 Million CHF | -13.57% |
| 2018 Q4 | 8.57 Million CHF | 0.0% |
| 2017 Q1 | 16.34 Million CHF | 8.98% |
| 2017 Q4 | 8.55 Million CHF | 0.0% |
| 2017 FY | 106.63 Million CHF | 2.01% |
| 2017 Q2 | 16.34 Million CHF | 0.0% |
| 2017 Q3 | 8.55 Million CHF | -47.64% |
| 2016 Q2 | 13.38 Million CHF | 0.0% |
| 2016 Q3 | 15 Million CHF | 12.11% |
| 2016 Q4 | 15 Million CHF | 0.0% |
| 2016 FY | 104.52 Million CHF | -6.49% |
| 2016 Q1 | 13.38 Million CHF | -12.27% |
| 2015 FY | 111.78 Million CHF | 272.54% |
| 2015 Q3 | 15.25 Million CHF | 28.33% |
| 2015 Q2 | 11.88 Million CHF | 0.0% |
| 2015 Q1 | 11.88 Million CHF | 33.13% |
| 2015 Q4 | 15.25 Million CHF | 0.0% |
| 2014 Q2 | 6.07 Million CHF | 0.0% |
| 2014 FY | 30 Million CHF | 43.66% |
| 2014 Q4 | 8.92 Million CHF | 0.0% |
| 2014 Q3 | 8.92 Million CHF | 46.94% |
| 2014 Q1 | 6.07 Million CHF | 24.52% |
| 2013 Q3 | 4.87 Million CHF | -12.32% |
| 2013 FY | 20.88 Million CHF | -55.24% |
| 2013 Q4 | 4.87 Million CHF | 0.0% |
| 2013 Q2 | 5.56 Million CHF | 0.0% |
| 2013 Q1 | 5.56 Million CHF | -38.04% |
| 2012 FY | 46.66 Million CHF | 0.0% |
| 2012 Q3 | 8.98 Million CHF | 0.0% |
| 2012 Q4 | 8.98 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -825.382% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2418.216% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1185.736% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -14.313% |
| GB Sciences, Inc. | 1.42 Million USD | -2278.232% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -892.165% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -15250.467% |
| Skye Bioscience, Inc. | 13.54 Million USD | -149.366% |
| Zenith Capital Corp. | 8.94 Million USD | -277.759% |
| Agentix Corp. | 1.37 Million USD | -2362.756% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -570.026% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3298.07% |
| ContraFect Corporation | 56.88 Million USD | 40.616% |
| CSL Limited | 3.44 Billion USD | 99.02% |
| CytoDyn Inc. | 18.05 Million USD | -87.081% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1712.033% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -8571.958% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 41.186% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -8031.097% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2149.352% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3558.109% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 9.321% |
| SQZ Biotechnologies Company | 85.61 Million USD | 60.543% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1548.993% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 61.073% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1058.446% |
| Mesoblast Limited | 5.9 Million USD | -472.399% |
| Marizyme, Inc. | 19.23 Million USD | -75.589% |
| Genus plc | 147.7 Million USD | 77.127% |
| Pharming Group N.V. | 225.49 Million USD | 85.018% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -305.121% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2184.562% |
| IMV Inc. | 37.7 Million USD | 10.412% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1110.705% |
| MultiCell Technologies, Inc. | 567.42 USD | -5953690.843% |
| ONE Bio Corp. | 6.44 Million USD | -424.264% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 60.692% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -36.69% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1819.84% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -402.872% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 135232.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -111.009% |
| Alpha Cognition Inc. | 9.7 Million USD | -248.077% |
| Enzolytics Inc. | 2.17 Million USD | -1450.029% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 97.797% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3135.92% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1304.737% |
| Genscript Biotech Corporation | 825.34 Million USD | 95.907% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -586.938% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -12807.774% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1275.912% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -19597.509% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1658.701% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -284.806% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -666.285% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -801.741% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1613.104% |
| EV Biologics, Inc. | 531.96 Thousand USD | -6250.642% |
| Q BioMed Inc. | 3.43 Million USD | -883.028% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -210.877% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 65.989% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -47.044% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1740.94% |
| HST Global, Inc. | 140.9 Thousand USD | -23875.388% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2429.745% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2903.174% |
| Halberd Corporation | 74.84 Thousand USD | -45039.093% |
| Resverlogix Corp. | 12.71 Million USD | -165.757% |
| Cell Source, Inc. | 4.32 Million USD | -681.047% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2039.038% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -362.131% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -193821.13% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -1269.529% |
| Kadimastem Ltd | 2.41 Million USD | -1301.719% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -697.067% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -18514.762% |
| LadRx Corporation | 3.81 Million USD | -786.276% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3558.109% |
| Affymax, Inc. | 39.38 Million USD | 14.226% |
| Itoco Inc. | 919.14 Thousand USD | -3575.489% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2919.035% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5992.01% |
| International Stem Cell Corporation | 5.27 Million USD | -540.922% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -784.338% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -134124.641% |
| Qrons Inc. | 643.67 Thousand USD | -5148.44% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2279.433% |
| SYBLEU INC | 160.87 Thousand USD | -20899.403% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1415.015% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4987.801% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1759.97% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -64074.993% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -165966.952% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 6.847% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1987.948% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -4491.111% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -985.921% |
| Neutra Corp. | 243.82 Thousand USD | -13755.656% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -93.521% |
| PureTech Health plc | 144.59 Million USD | 76.636% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -64.876% |
| IXICO plc | 4.7 Million USD | -617.718% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -284.029% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 71.309% |
| CSL Limited | 3.89 Billion USD | 99.132% |
| Cellectis S.A. | 97.32 Million USD | 65.287% |